PROTAC IRAK4 degrader-1 |
| Catalog No.GC62197 |
PROTAC IRAK4 degrader-1 est un dégradeur de kinase 4 (IRAK4) associé au récepteur de l'interleukine-1 PROTAC À base de Cereblon extrait du brevet US20190192668A1 composé I-210, produit une dégradation de 20 À 50 % et > 50 % d'IRAK4 À 0,01, 0,1 et 1 μM dans des cellules OCI-LY-10, respectivement.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2360533-90-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PROTAC IRAK4 degrader-1 is a PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1 Compound I-210, makes 20-50%, and >50% IRAK4 degradation at 0.01, 0.1, and 1 μM in OCI-LY-10 cells, respectively[1].
[1]. Nello Mainolfi, et al. Irak degraders and uses thereof. US20190192668A1.
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *